Meeting Banner
Abstract #4795

TRUS Biopsy Has a Lower Cancer Detection Rate in Large Prostate Volumes: Can In-Bore MRI-Guided Biopsy Do Better?

Kareem K Elfatairy1, Christopher P Filson2, Adeboye O Osunkoya3, Rachel G Geller3, and Sherif G Nour1

1Radiology, Emory University-School of Medicine, Atlanta, GA, United States, 2Urology, Emory University-School of Medicine, GA, United States, 3Pathology, Emory University-School of Medicine, Atlanta, GA, United States

TRUS biopsy known to have low cancer detection rates in patients with large prostate volumes. With the proved advantages of MRI guided biopsy (MRGB), it may offer a better alternative to those patients. We compared between cancer detection rates of TRUS biopsy and MRGB in 49 patients as related to their prostate volumes. MRGB showed better detection of clinically significant cancers in prostate volumes between 30-59 mL . Adopting MRGB in patients with gland volumes ≥ 30 mL may save patients the need for repeated TRUS biopsies, provide better disease risk stratification, and reduce the healthcare costs associated with unnecessary biopsies.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.

Keywords